SEARCH:   Advanced

Blood, 1 October 2008, Vol. 112, No. 7, pp. 2694-2702. Prepublished online as a Blood First Edition Paper on July 16, 2008; DOI 10.1182/blood-2007-09-111658. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2007-09-111658v1 112/7/2694    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Habermann, T. M. Articles by Cerhan, J. R. Search for Related Content PubMed PubMed Citation Articles by Habermann, T. M. Articles by Cerhan, J. R. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Thomas M. Habermann1, Sophia S. Wang2, Matthew J. Maurer1, Lindsay M. Morton2, Charles F. Lynch3, Stephen M. Ansell1, Patricia Hartge2, Richard K. Severson4, Nathaniel Rothman2, Scott Davis5, Susan M. Geyer1, Wendy Cozen6, Stephen J. Chanock2, and James R. Cerhan1 1 Mayo Clinic College of Medicine, Rochester, MN; 2 National Cancer Institute, Bethesda, MD; 3 University of Iowa, Iowa City; 4 Wayne State University, Detroit, MI; 5 Fred Hutchinson Cancer Research Center, Seattle, WA; and 6 University of Southern California, Los Angeles To evaluate the hypothesis that host germ line variation in immune genes is associated with overall survival in diffuse large B-cell lymphoma (DLBCL), we genotyped 73 single nucleotide polymorphisms (SNPs) from 44 candidate genes in 365 DLBCL patients diagnosed from 1998 to 2000. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of SNPs with survival after adjusting for clinical factors. During follow-up, 96 (26%) patients died, and the median follow-up was 57 months for surviving patients. The observed survival of this cohort was consistent with population-based estimates conditioned on surviving 12 months. An IL10 haplotype (global P = .03) and SNPs in IL8RB (rs1126580; HRAG/GG = 2.11; CI, 1.28-3.50), IL1A (rs1800587; HRCT/TT = 1.90; CI, 1.26-2.87), TNF (rs1800629; HRAG/GG = 1.44; CI, 0.95-2.18), and IL4R (rs2107356; HRCC/CT = 1.97; CI, 1.01-3.83) were the strongest predictors of overall survival. A risk score that combined the latter 4 SNPs with clinical factors was strongly associated with survival in a Cox model (P = 6.0 x 10–11). Kaplan-Meier 5-year survival estimates for low, intermediate-low, intermediate-high, and high-risk patients were 94%, 79%, 60%, and 48%, respectively. These data support a role for germ line variation in immune genes, particularly genes associated with a proinflammatory state, as predictors of late survival in DLBCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. A. Wilcox, D. A. Wada, S. C. Ziesmer, S. F. Elsawa, N. I. Comfere, A. B. Dietz, A. J. Novak, T. E. Witzig, A. L. Feldman, M. R. Pittelkow, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells Blood, October 1, 2009; 114(14): 2936 - 2944. [Abstract] [Full Text] [PDF] N. Schoof, F. von Bonin, S. Zeynalova, M. Ziepert, W. Jung, M. Loeffler, M. Pfreundschuh, L. Trumper, and D. Kube Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial Ann. Onc., September 1, 2009; 20(9): 1548 - 1554. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020